Scientists Discover Molecular Switch Fueling Alzheimer’s Brain Inflammation

Here is your publish-ready WordPress Gutenberg block HTML article based on the verified primary sources:

A newly discovered molecular “switch” may hold the key to stopping the chronic brain inflammation that drives Alzheimer’s disease, according to preclinical research published in Cell Chemical Biology on April 23, 2026. Scientists at Scripps Research have identified how a chemical modification to a protein called STING keeps the brain’s immune system in overdrive, damaging the connections between nerve cells that are critical for memory and learning.

The study reveals that in Alzheimer’s disease, STING—a protein normally involved in detecting infections—undergoes a chemical change called S-nitrosylation (SNO). This modification, triggered by aging, toxic proteins like amyloid-beta, or environmental factors, causes STING to cluster into inflammatory complexes that trigger ongoing neuroinflammation. Unlike general immune suppression, blocking this specific modification at a single site (cysteine 148) in mouse models reduced inflammation without compromising the body’s ability to fight infections.

Senior author Stuart Lipton, the Step Family Foundation Endowed Chair at Scripps Research and a clinical neurologist, described the findings as “a new and important therapeutic target for Alzheimer’s disease.” The research builds on growing evidence that chronic inflammation in the brain contributes to synaptic loss—the hallmark of cognitive decline in Alzheimer’s.

How the “Switch” Works

The team discovered that nitric oxide—a molecule involved in cellular signaling—binds to STING, creating a modified form called “SNO-STING.” This altered protein triggers persistent activation of brain immune cells (microglia), which normally help clear debris but instead release inflammatory signals that damage synapses in Alzheimer’s models.

In experiments using human Alzheimer’s brain cells and mouse models, blocking S-nitrosylation of STING at cysteine 148 protected synaptic connections and reduced neuroinflammation. The approach contrasts with broad anti-inflammatory drugs, which often weaken immune defenses against infections.

Why This Matters for Alzheimer’s Research

Alzheimer’s disease is characterized by the progressive loss of synapses—the junctions where neurons communicate. While amyloid plaques and tau tangles have long been studied, inflammation driven by overactive immune responses is increasingly recognized as a key contributor to cognitive decline. This study identifies a precise molecular pathway that could be targeted to interrupt this cycle.

“This is the first time we’ve shown that a specific chemical modification to STING is driving the chronic inflammation seen in Alzheimer’s,” said Lauren Carnevale, a postdoctoral researcher in Lipton’s lab and lead author of the study. “By blocking this modification, we’re essentially turning off the switch that keeps the immune system stuck in overdrive.”

“This is a new and important therapeutic target for Alzheimer’s disease.”

— Stuart Lipton, Step Family Foundation Endowed Chair, Scripps Research

What Comes Next

The findings are still preclinical, meaning they have not yet been tested in humans. However, the specificity of the target—cysteine 148 on STING—suggests it could lead to drugs with fewer side effects than current anti-inflammatory approaches. Researchers are now exploring whether similar mechanisms operate in other neurodegenerative diseases, such as Parkinson’s or frontotemporal dementia.

For now, the study underscores the importance of inflammation in Alzheimer’s progression and offers hope that precision medicine—targeting specific molecular pathways rather than broad symptoms—could one day slow or even halt the disease. Experts caution that while promising, such therapies are likely years away from clinical use.

For individuals concerned about Alzheimer’s risk, maintaining overall brain health through regular exercise, a balanced diet, cognitive engagement and managing vascular health remains the most evidence-based approach.